Immuneering Corp — Form 10-Q
Filed October 29, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
This filing consists solely of standard SOX 302/906 certifications by CEO Benjamin J. Zeskind and CFO Andrew Gengos for Q3 2026 (ended Sept 30, 2026), dated Oct 29, 2026. The certifications affirm financial statement accuracy and internal control effectiveness but contain no operational, financial, or strategic disclosures—only boilerplate attestations.
Why this rating
Routine certification exhibits with no substantive business content; administrative filing requirement only.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.